Ultragenyx (RARE) reported $207 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 25.6%. EPS of -$1.29 for the same period compares to -$1.39 a year ago.
The reported revenue represents a surprise of +2.01% over the Zacks Consensus Estimate of $202.92 million. With the consensus EPS estimate being -$1.20, the EPS surprise was -7.32%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales- Dojolvi: $32 million versus the seven-analyst average estimate of $30.28 million. The reported number represents a year-over-year change of +2.9%.
- Revenues- Product sales- Evkeeza: $17 million versus $16.37 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +63.9% change.
- Revenues- Product sales- Mepsevii: $13 million versus $10.81 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +63% change.
- Revenues- Total Crysvita revenue: $145 million versus the six-analyst average estimate of $135.25 million.
- Revenues- Product sales: $102 million versus $114.76 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +41.9% change.
- Revenues- Royalty revenue: $105 million compared to the $91.57 million average estimate based on five analysts. The reported number represents a change of +12.9% year over year.
View all Key Company Metrics for Ultragenyx here>>>
Shares of Ultragenyx have returned -0.8% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
